# Debate Matchup Judgment Report

**Claude Fable 5 (high)** vs **Qwen 3.8 Max**

- Paired result: **Claude Fable 5 (high)**
- Mean entertainment: `7.50 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Over the next five years, allowing Medicare to cover GLP-1–class anti-obesity drugs broadly will reduce total US healthcare spending after accounting for drug costs.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0582__claude-fable-5-high__qwen3.8-max__s0__tpl_placement_active_20260320f.md): PRO = **Claude Fable 5 (high)**, CON = **Qwen 3.8 Max**
- [Debate B transcript](../../../transcripts/prop_0582__qwen3.8-max__claude-fable-5-high__s1__tpl_placement_active_20260320f.md): PRO = **Qwen 3.8 Max**, CON = **Claude Fable 5 (high)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_glm53_coverage_20260904a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0582__claude-fable-5-high__qwen3.8-max__s0__tpl_placement_active_20260320f.md)
- Roles: PRO = **Claude Fable 5 (high)**, CON = **Qwen 3.8 Max**
- Judged result: Split `2-1` for **Qwen 3.8 Max**.
- Entertainment scores: `7`, `7`, `8`
- Mean signed raw margin (PRO+): `-0.60`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Grok 4.5 (high) | A = Claude Fable 5 (high) (PRO); B = Qwen 3.8 Max (CON) | Qwen 3.8 Max | -1.2 | -1.36 | 7.0 |
| Kimi K2.6 | A = Claude Fable 5 (high) (PRO); B = Qwen 3.8 Max (CON) | Claude Fable 5 (high) | +1.4 | +1.59 | 7.0 |
| Muse Spark 1.1 (high) | A = Qwen 3.8 Max (CON); B = Claude Fable 5 (high) (PRO) | Qwen 3.8 Max | -2.0 | -2.12 | 8.0 |

### Judge Notes

- **Grok 4.5 (high)** (A = Claude Fable 5 (high) (PRO); B = Qwen 3.8 Max (CON)): CON held the burden cleaner: broad coverage creates certain near-term drug spend whose break-even requires high expected avoided care per treated month across the full pool, not just trial-like tails. PRO's discontinuation contradiction and sick-skew points landed, and using CON's own $20B/two-thirds framing was sharp, but PRO never bridged average (not peak) event rates to the $400/month bar inside five years after dilution, fade, and non-avoidable baseline spend. CON's expected-value pressure and average-vs-tail distinction stayed live and decisive.
  Most decisive rebuttal noted: B's R2 expected-value math (2% MI example yielding ~$100 vs $400 break-even) directly undercut PRO's tail-event substitution.
- **Kimi K2.6** (A = Claude Fable 5 (high) (PRO); B = Qwen 3.8 Max (CON)): PRO built the stronger path to victory by exposing an internal tension in CON's case between continuous-treatment cost projections and high discontinuation, then converting that into a cost-capping argument. PRO successfully pressed CON to commit to specific numbers in Rebuttal 2, and in the closing turned those numbers—roughly $20 billion over five years and $400 per treated month—against CON by showing that sick-skewed uptake concentrates spending on the highest-risk beneficiaries, where one avoided acute event pays for many treatment-years. CON's fiscal caution and expected-value framing were competent, but never fully neutralized PRO's per-month break-even logic or the structural point that broad eligibility does not mean universal utilization.
  Most decisive rebuttal noted: PRO's first rebuttal exposing CON's tension between "millions continuously treated" and "rampant discontinuation," which PRO leveraged into a decisive cost-capping mechanism; and PRO's closing synthesis using CON's own $20 billion commitment to show the math breaks in PRO's favor for the high-risk treated majority.
- **Muse Spark 1.1 (high)** (A = Qwen 3.8 Max (CON); B = Claude Fable 5 (high) (PRO)): CON won the expected-value ledger clash. PRO framed savings around dramatic tail events (one prevented MI ~$25k, one delayed dialysis $90k/year paying for 5-18 treatment-years) but CON showed broad coverage must clear ~$400 per treated month on average, not in tail cases. With 2% annual MI risk, a 20% RRR saves ~$100/year, and much of the $15k average spend CON acknowledged is not GLP-1-avoidable within five years. PRO's discontinuation-halves-cost argument was turned: paying for months without durable benefit is the worst fiscal shape, and sick-skewed uptake under broad eligibility shrinks national savings if uptake is throttled. PRO never supplied broad-population avoided-care per month to meet its own break-even.
  Most decisive rebuttal noted: CON's Rebuttal 2 expected-value math: 4M treatment-years ≈$20B over 5 years at $400/mo, requiring $400/month avoided care, vs $100/year from 2% MI risk – exposing PRO's tail-case averaging fallacy as decisive.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0582__qwen3.8-max__claude-fable-5-high__s1__tpl_placement_active_20260320f.md)
- Roles: PRO = **Qwen 3.8 Max**, CON = **Claude Fable 5 (high)**
- Judged result: Unanimous `3-0` for **Claude Fable 5 (high)**.
- Entertainment scores: `8`, `8`, `7`
- Mean signed raw margin (PRO+): `-2.50`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Grok 4.5 (high) | A = Qwen 3.8 Max (PRO); B = Claude Fable 5 (high) (CON) | Claude Fable 5 (high) | -2.3 | -2.61 | 8.0 |
| Kimi K2.6 | A = Qwen 3.8 Max (PRO); B = Claude Fable 5 (high) (CON) | Claude Fable 5 (high) | -2.2 | -2.49 | 8.0 |
| Muse Spark 1.1 (high) | A = Claude Fable 5 (high) (CON); B = Qwen 3.8 Max (PRO) | Claude Fable 5 (high) | -3.0 | -3.19 | 7.0 |

### Judge Notes

- **Grok 4.5 (high)** (A = Qwen 3.8 Max (PRO); B = Claude Fable 5 (high) (CON)): CON won by locking the dilemma on "broadly" (either already-arriving narrow coverage or diluted low-risk pool) and converting PRO's own cascade offset numbers into a clean 3-5x shortfall versus trial NNT arithmetic inside five years. PRO's high-risk reframing and cascade emphasis were live but never closed the gap or escaped the definitional trap.
  Most decisive rebuttal noted: B4.2 turning A4.2's 30-50 patient-years vs $150k against the 150-200 NNT from trials
- **Kimi K2.6** (A = Qwen 3.8 Max (PRO); B = Claude Fable 5 (high) (CON)): CON checkmated PRO by combining PRO's own cost-per-cascade estimate with trial-derived effect sizes to show drug spending exceeds savings three- to five-fold even in the highest-risk population. PRO never recovered from this arithmetic trap or escaped CON's dilemma that "broad" coverage either adds low-risk beneficiaries (worsening the ratio) or high-risk beneficiaries already being covered (no marginal fiscal change). PRO's closing simply relabeled the denominator as "wrong" without disputing the figures, while CON crystallized the comparison cleanly.
  Most decisive rebuttal noted: CON's Rebuttal 2 (B4.2), which accepted PRO's $150,000 cascade figure and demonstrated that dividing it by the 150–200 patient-years of therapy needed per event prevented still yields drug costs several times larger than savings—a decisive use of PRO's own ledger that PRO never addressed in closing.
- **Muse Spark 1.1 (high)** (A = Claude Fable 5 (high) (CON); B = Qwen 3.8 Max (PRO)): CON wins on arithmetic. PRO conceded one $150k cascade offsets only 30-50 patient-years [B4.2] while high-risk trials need ~150-200 patient-years per event prevented [A2/A4]. CON divided PRO's own figures to show 3-5x cost vs savings even in best case, and closed dilemma: broadly means low-risk (worse) or narrowly means motion adds nothing to existing diabetes/CV coverage. PRO never answered that math in B5.
  Most decisive rebuttal noted: A4.1-A4.2 turned PRO's 30-50 patient-years concession against 150-200 patient-years NNT to prove net spending increase even at $150k cascade, collapsing PRO's case.

## Technical metadata

- Evaluation scope: `judge_judge_blend_glm53_coverage_20260904a__debate_all_templates`
- Topic ID: `prop_0582`
- Side-swap group ID: `prop_0582__claude-fable-5-high__qwen3.8-max__tpl_placement_active_20260320f`
- Raw paired winner: **Claude Fable 5 (high)**
- Mean normalized margin for Claude Fable 5 (high): `+1.06`
- Complete side swap: `yes`
- Included in ratings: `yes`
